Insider buying last 90 days
No open-market insider purchases were filed for KYMR in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every KYMR insider filing, plotted on the chart in Gekko.Open KYMR in Gekko
NASDAQ: KYMR
Kymera Therapeutics (KYMR) Stock Analysis & Forecast
Sep 28 close
$112.00+0.05 (0.0%)
Gekko Brief
AI summaryKymera Therapeutics draws a string of analyst attention this week. Goldman Sachs resumes coverage with an Early-Stage Biotech rating, noting the stock's 120% gain over the past year, while Piper Sandler reiterates an Overweight rating with a $140 price target ahead of Phase 2 trial data for KT-621 in atopic dermatitis expected in the fourth quarter. Stifel also raises its price target by 29%, citing the clinical-trial outlook and pointing to a market value of $9.78 billion.
KYMR closes at $112.00, sitting between its 50-day average of $114.58 and 200-day average of $92.59, with a one-month return of -6.8% but a six-month gain of 43.3%. The GekkoIndex reads 61.4, placing the stock in the Accumulation zone, up 6 points over the last five readings. Price sits close to Gekko Fair Value of $113.91, a gap of -1.7%.
The next earnings report is due 3 November 2026, 35 days out and outside a typical 20-trading-day hold; the last report on 5 August beat estimates modestly with a 1.9% reaction. No insider, Congress or unusual options activity appears in the current windows. Seasonally, the next 20 trading days have averaged -0.3% over 5 years, rising in 2 of them. Analyst sentiment remains skewed toward buy ratings among the 16 firms covering the stock, with a consensus target of $138.64.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Kymera Therapeutics price vs fair value
Close $112.00200-day averageGekko Fair Value $113.91
Kymera Therapeutics quick facts
- Market cap
- $9.21B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$3.27
- Revenue, TTM
- $105.0M
- Profit margin
- -285.3%
- Dividend yield
- —
- Beta
- 1.97
- Volume
- 723,650 avg 747,495
- 1-year return
- +108.4%
- Typical daily move
- ±4.5%
- Typical 20-day move
- ±11.9%
- 50-day average
- $114.58
- 200-day average
- $92.59
- Next earnings
- Nov 3 before open
- Shares outstanding
- 82.26M
Kymera Therapeutics swing-trade checklist
Kymera Therapeutics scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendmixed
Averages disagree
Close $112.00 sits between the 50-day ($114.58) and 200-day ($92.59) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
61.4, Accumulation
Reading 61.4 is in the Accumulation zone.
See the GekkoIndex - Fair valuemixed
1.7% below
Price is within 5% of Gekko Fair Value (1.7% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 35 days
Next report Nov 3, 2026, 35 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−0.3% on average
From this point in the calendar, the next 20 trading days averaged −0.3% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Kymera Therapeutics stock chart and price history
Kymera Therapeutics closed at $112.00 on Sep 28, 2026, +108.4% over the past year, inside a 52-week range of $53.20 to $130.05.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −6.8%
- 3 months
- +2.5%
- 6 months
- +43.3%
- 1 year
- +108.4%
The full KYMR chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open KYMR in Gekko
Follow Kymera Therapeutics through every session
Put KYMR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track KYMR in GekkoFree for 7 days. No credit card required.
Kymera Therapeutics GekkoIndex: the smart money zone
Kymera Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 61.4, in the Accumulation zone, up 6 points over five sessions.
61.4Accumulation
Up 6 points over five sessions, from the Neutral zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 23 | +6.4% | +24.6% | ||
| Accumulation (current zone) | 191 | +2.0% | +7.5% | ||
| Neutral | 384 | +0.8% | +3.7% | ||
| Distribution | 70 | +2.7% | +4.7% | ||
| Selling | 4 | Too few readings yet | |||
Average KYMR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the KYMR price, zone by zone.Track KYMR in Gekko
Is Kymera Therapeutics stock overvalued? Gekko Fair Value
Kymera Therapeutics trades 1.7% below Gekko Fair Value of $113.91, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Kymera Therapeutics shares are worth, recalculated every trading day.
$113.91
Gekko Fair Value, Sep 26, 2026
1.7% below fair value · About fair value
Gekko Fair Value on every chart, with the gap to price updating daily.Open KYMR in Gekko
Kymera Therapeutics insider and Congress trading
No open-market insider purchases were filed for Kymera Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in KYMR were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for KYMR, plotted on the chart in Gekko.Open KYMR in Gekko
Hedge funds and billionaires quarter ended Mar 31
0of the funds Gekko tracks hold KYMR.
0added0opened0trimmed2sold out
Which funds are on each side, name by name.Unlock in Gekko
Kymera Therapeutics earnings: next date and track record
Kymera Therapeutics reports on Nov 3, 2026, before the open (35 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 3, 2026
Expected before the open, 35 days away
- EPS estimate
- −$1.25
- Revenue estimate
- $3.10M
4 of 8reports beat the EPS estimate
±3%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- Kymera Therapeutics reported strong Q2 2026 momentum highlighted by completing enrollment in their Phase 2b atopic dermatitis (AD) trial approximately 6 months ahead of schedule. The company is advancing their STAT6 program alongside a broader pipeline leveraging targeted protein degradation and small molecule capabilities. A leadership transition is underway with CMO Jared Gollob retiring and Terence Rooney stepping into the role.
- Guidance
- Kymera now expects Phase 2b AD trial top-line data by year-end 2026 and Phase 3 initiation around mid-2027, both approximately 6 months earlier than previously planned due to accelerated enrollment completion.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | −$0.62 est −$0.64 | $65.00M est $32.78M | +1.9% |
| Apr 30, 2026 | −$0.71 est −$0.86 | $34.37M est $8.27M | −1.0% |
| Feb 26, 2026 | −$0.97 est −$0.78 | $2.87M est $15.05M | +0.7% |
| Nov 4, 2025 | −$0.90 est −$0.71 | $2.76M est $14.45M | +0.3% |
| Aug 11, 2025 | −$0.95 est −$0.83 | $11.48M est $17.13M | −1.8% |
| May 9, 2025 | −$0.82 est −$0.92 | $22.10M est $12.38M | +4.5% |
| Feb 27, 2025 | −$0.88 est −$0.76 | $7.39M est $16.68M | −11.3% |
| Oct 31, 2024 | −$0.82 est −$0.83 | $3.74M est $15.21M | −2.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Kymera Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Kymera Therapeutics is $138.64, +23.8% from the last close, from 16 firms rating the stock in the last 90 days.
$138.64consensus 12-month target, +23.8% from the last close
Now $112.00Avg $138.64
Low $112High $180
Each firm’s latest rating in the last 90 days: 16 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 28 | J.P. Morgan | $140 | +25.0% |
| Sep 23 | Piper Sandler | $140 | +25.0% |
| Sep 22 | Stifel Nicolaus | $152 | +35.7% |
| Sep 14 | Bank of America Securities | $144 | +28.6% |
| Sep 10 | Wolfe Research | $180 | +60.7% |
+7.5%average 20-day move after past Accumulation readings
−0.3%average move over the next 20 trading days in the last 5 years
±4.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Kymera Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Kymera Therapeutics averaged −0.3% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.8% | 2 of 5 |
| Next 10 trading days | −5.2% | 1 of 5 |
| Next 15 trading days | −3.6% | 2 of 5 |
| Next 20 trading days | −0.3% | 2 of 5 |
| Next 30 trading days | +12.4% | 5 of 5 |
For scale, KYMR’s typical 20-trading-day move in either direction is about 11.9%.
Kymera Therapeutics market cap and key statistics
Kymera Therapeutics’s market cap is $9.21B and revenue of $105.0M over the last twelve months.
Valuation
- Market cap
- $9.21B
- EPS, TTM
- −$3.27
- Gekko Fair Value
- $113.91
Trading
- Volume
- 723,650
- Avg volume, 20 days
- 747,495
- 52-week high
- $130.05
- 52-week low
- $53.20
- Shares outstanding
- 82.26M
Financials
- Revenue, TTM
- $105.0M
- Profit margin
- -285.3%
- Return on equity
- -24.1%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.97
- Typical daily move
- ±4.5%
- Typical 20-day move
- ±11.9%
Kymera Therapeutics stock news this week
Coverage of Kymera Therapeutics this week reads positive: 3 positive, 1 neutral and 0 negative headlines.
- Goldman Sachs resumes Kymera Therapeutics stock coverage By Investing.comInvesting.com Canada, Sep 24
- Piper Sandler reiterates Kymera Therapeutics stock rating at $140 By Investing.comInvesting.com Canada, Sep 23
- Kymera Therapeutics stock gains as Stifel lifts its targetAD HOC NEWS, Sep 22
- (KYMR) Volatility Zones as Tactical TriggersStock Traders Daily, Sep 22
Kymera Therapeutics peers
Kymera Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
Kymera Therapeutics stock FAQ
What is Kymera Therapeutics’s market cap?
Kymera Therapeutics’s market cap is $9.21B at the Sep 28, 2026 close of $112.00, with 82.26M shares outstanding.
What is the Kymera Therapeutics stock forecast?
The consensus analyst 12-month price target for Kymera Therapeutics is $138.64, +23.8% from the last close. Of the 16 firms that rated the stock in the last 90 days, 14 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Kymera Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Kymera Therapeutics is about fair value: the Sep 28, 2026 close of $112.00 is 1.7% below Gekko Fair Value of $113.91. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Kymera Therapeutics report earnings next?
Kymera Therapeutics is expected to report on Nov 3, 2026, before the market opens (35 days away). Analysts expect earnings of −$1.25 per share on revenue of $3.10M. Kymera Therapeutics beat the earnings estimate in 4 of its last 8 reports, moving 3% on average across the report.
What is Kymera Therapeutics’s 52-week high and low?
Kymera Therapeutics’s 52-week high is $130.05 and its 52-week low is $53.20; it closed at $112.00 on Sep 28, 2026, +108.4% over the past year.
Is Kymera Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and earnings risk), 2 as mixed (trend and fair value) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Kymera Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.